Greenville SC

  • Sam Patrick posted an article
    Greenville, SC gains more accolades as a key cog in the state's emerging knowledge economy see more

    Greenville and South Carolina are in the national spotlight again as among America's emerging knowledge economy destinations.  SCBIO supporters Zylo Therapeutics, KIYATEC, VentureSouth and Chartspan are among the features companies in Bloomberg Businessweek's fabulous article.  Read on for the full story.

     

  • Sam Patrick posted an article
    KIYATEC and OHSU initiate patient enrollment into key oncology clinical trial. see more

    GREENVILLE, S.C.-- KIYATEC, Inc., today announced that Oregon Health & Science University (OHSU) Knight Cancer Institute has initiated patient enrollment into KIYATEC’s clinical study, 3D-PREDICT, to validate the company’s test as a patient-specific predictor of response to cancer therapies for solid tumors.

    In this clinical study, the test analyzes a patient’s live cancer cells, grown in KIYATEC’s laboratory within a biologically-relevant 3D microenvironment, to determine whether or not those cells respond to guideline-recommended cancer drugs. Evidence from the company’s earlier pilot study established a correlation between patient-specific predicted tumor response and actual patient clinical response to cancer therapy. The 3D-PREDICT study is a fully prospective, multi-institutional effort to validate the predictive accuracy of the test and correlate response predictions to clinical outcomes among patients with newly diagnosed and relapsed ovarian cancer, glioblastoma and certain rare tumors.

    At present, the OHSU Knight Cancer Institute is enrolling newly diagnosed and relapsed ovarian cancer patients into the 3D-PREDICT Study.

    “As a pioneer in personalized cancer care, the OHSU Knight Cancer Institute is deeply committed to optimizing appropriate therapy for our patients as early as possible following diagnosis, when the disease is most treatable,” said Dr. Koen De Geest, lead investigator of the clinical trial at OHSU. “Five-year survival among high-grade ovarian cancer patients is 30%, and we believe this test has the potential to help improve outcomes in the clinic.”

    “With cancer treatment, and especially ovarian cancer, time is of the essence and being able to measure patient-specific evidence of response and non-response before treatment begins can truly change the future of cancer care,” said Matthew Gevaert, CEO of KIYATEC. “We welcome OHSU to our clinical study and their participation will be integral as we work to deliver accurate predictions of patient response to cancer therapies, reducing the need for patients to undergo treatments that may not work.”

    The 3D-PREDICT study is anticipated to continue through 2022. Details on the trial can be found on https://clinicaltrials.gov/ct2/show/NCT03561207.

    About KIYATEC, Inc.
    KIYATEC is changing the future of cancer care by accurately predicting patient-specific response and non-response to therapies before treatment begins. Wasted time is the enemy of cancer patients and there is currently no way to accurately predict which cancer patients will respond to standard oncology treatments. KIYATEC has developed a validated process to use a cancer patient’s own live cells to 
    accurately predict treatment response prior to beginning treatment.

  • Sam Patrick posted an article
    Humimic is opening doors to a world of medical research from right here in South Carolina see more

    Accompanied by a contingent of life sciences leaders from SCBIO, the South Carolina Department of Commerce, Upstate Alliance, the Charleston Regional Development Alliance and others, South Carolina is making its presence felt at Arab Health 2019 -- the global medical and life sciences conference held annually in Dubai.  And Greenville's own Humimic Medical is making its own presence felt as well.

    Imagine a gelatin solution that mimics soft human tissue. One that doesn’t require refrigeration, and that opens doors to a world of medical industry research and training without the obstacles that come with cadavers.

    The product exists, developed eight years ago by Joel Edwards in his Arkansas basement. It was sparked by an idea, and initially sold to defense companies for testing under the name Clear Ballistics.

    In recent years, physicians and medical researchers took notice, prompting the spinoff of a company called Humimic Medical.

    Read on for the full story from Greenville Business Magazine.

     

  • Sam Patrick posted an article
    IVC, which produces dietary supplements, prescription and OTC products, is expanding. see more

    Company produces high quality dietary supplements, plus nutritional, prescription and OTC products, for leading U.S. and global retailers and contract customers

     

    GREENVILLE, S.C. June 18, 2018 – International Vitamin Corporation (IVC), which produces high quality dietary supplements along with nutritional, prescription and OTC products, will invest several million dollars and add a significant number of positions to expand operations at its Greenville County, S.C. facilities over the next several years.

    Founded more than 55 years ago, IVC produces high quality dietary supplements for leading food, drug, mass and club retailers in the United States. The company also produces nutritional, prescription and OTC products for contract customers around the world. IVC’s recognized ability to deliver on innovation, quality and supply chain efficiency has enabled IVC to become one of the largest and fastest growing private label nutritional supplement companies in the nutritional marketplace.

    “This expansion of our Greenville County presence represents an important step in the growth of our business,” said Steven Dai, President and CEO for International Vitamin Corporation. 

    “We have found Greenville County and the Upstate a welcoming and pro-business location to expand our business, serve our customers and accelerate IVC’s success as we focus our efforts on meeting growing demand from our customers,” Dai added.  “We appreciate the support of the Greenville Area Development Corporation, the city of Greenville, the South Carolina Department of Commerce, and all who joined to make this announcement a reality.”

    IVC will expand its operations at 4615 Dairy Road and 4611 Dairy Road in Greenville County, already employing more than 380 associates.  IVC will create “a meaningful number of additional skilled and professional positions in Greenville County over the next several years,” said Jill Stambler, Vice President Human Resources.

    “Greenville County is pleased with International Vitamin Corporation's decision to expand its business operations in Greenville County by producing well known dietary supplements and pharmaceutical products to the US and international markets as it has for over 50 years,” said H.G. “Butch” Kirven, Chairman of Greenville County Council. “This expansion means significant additional capital investment by the company here, coupled with a commitment to increasing job opportunities for local citizens.  The company's decision reflects the high caliber of Greenville county's workforce, our low tax rates, and the unparalleled quality of life unique to our area.”

    “IVC’s focus on the vitamins, minerals and supplements market and innovations in both manufacturing and supply chain show that our community continues to be a profitable place to do business,” said City of Greenville Mayor Knox White. “The expansion of their manufacturing facility along the I-85 corridor is further affirmation that Greenville is open for business and we are thankful for the IVC family’s trust and continued investment.”

    Hiring details for the additional positions to be filled will be announced in the near future, according to Stambler.  She adds, “We are currently looking for a number of positions on different shifts.”  Some include: 

    • Set-up Mechanics
    • Material Handlers
    • Operators
    • Turret Drivers
    • Manufacturing Supervisors
    • Warehouse Clerk
    • Warehouse Order Pickers
    • Warehouse Shippers

    Interested candidates may apply directly at the IVC website by visiting http://ivccareers.com.

    For more information about International Vitamins Corporation, visit them at www.ivcinc.com.

     

  • Sam Patrick posted an article
    KIYATEC growth supports upcoming programs to better predict patient response to oncology drugs see more

    GREENVILLE, SC. – May 29, 2018 – KIYATEC, Inc., a privately held company changing the future of cancer care by predicting patient response to oncology drugs prior to treatment, today announced an expansion of its leadership team with the appointment of two industry veterans. Charlene Knape has joined the company as Vice President of Clinical Affairs, and Timothy Decker as Vice President Commercial Operations.

    Mr. Decker, a twenty year industry leader with a proven track record of developing and commercializing oncology diagnostic services and pharmaceuticals, has assumed responsibility for pre-launch commercial strategic development along with tactical planning and execution to drive clinical product launches. Mr. Decker held roles of increasing responsibility in strategic and tactical marketing for a decade at G.D. Searle and Abbott Laboratories before joining Genomic Health, Inc.  Over an eight year span, he played a lead role as Director and Senior Director in the global launch, marketing, reimbursement and sales of Oncotype DX molecular diagnostic tests in breast, colon and prostate cancers. Mr. Decker subsequently served as Vice President of Marketing at Castle Biosciences, Inc., where he drove corporate and pipeline strategy, as well as in-line product strategy and revenue growth for its molecular diagnostic tests in melanoma. He joins the company from Mexico City-based Grupo Fármacos Especializados, where he served as Division Head, Oncology Diagnostics, responsible for developing reimbursement pathways and securing positive coverage decisions among public and private sector payers.

    With more than 25 years of experience working with diagnostic companies, Ms. Knape is responsible for leading the clinical development programs and clinical operations for KIYATEC’s pipeline for ovarian cancer, glioblastoma, rare tumors and triple negative breast cancer. She most recently served as Senior Director, Clinical Development for Inivata, a clinical cancer genomics company utilizing liquid biopsies for comprehensive genomic profiling of tumors. Prior to this, Ms. Knape served in Becton Dickinson’s Corporate Clinical Development group, responsible for global clinical quality and contracts. Ms. Knape spent five years with Micell Technologies as Senior Director of Clinical Affairs where she managed all global clinical activities for first-in-human and CE Marking studies for an implantable cardiovascular device from initiation through successful regulatory submission. As the company’s lead in clinical operations, Ms. Knape also built the team and initiated a 1,400-patient study in Europe and a 400-patient study in China. Previously, Ms. Knape served as Vice President, Clinical Affairs at EndoTex Interventional Systems, led the clinical functions for Avocet Medical and Somnus Medical Technologies and held clinical affairs positions in the Companion Diagnostics and Biorepository at LabCorp.

    “At this pivotal time in the company’s growth, we are thrilled to welcome Charlene and Tim to KIYATEC. These two newly created positions are critical as we expand our clinical programs in key therapeutic areas and further strengthen our plan for the broad adoption of our patient-specific response prediction tests,” said Dr. Matthew Gevaert, CEO of KIYATEC. “Their expertise and industry knowledge is unparalleled and they will be instrumental as KIYATEC continues toward its path of changing the future of cancer care by predicting patient response to chemotherapy before treatment begins. I’m so glad to have Tim and Charlene on our team as we move toward our goal of commercialization and helping patients receive optimal treatment at the earliest possible time.”

    KIYATEC will be attending the American Society of Clinical Oncology (ASCO) meeting being held June 1-5 in Chicago.

    About KIYATEC, Inc.

    KIYATEC is changing the future of cancer care by accurately predicting patient-specific response and non-response to chemotherapy drugs before treatment begins. Wasted time is the enemy of cancer patients and there is currently no way to accurately predict which cancer patients will respond to standard oncology treatments. KIYATEC has developed a validated process to use a cancer patient’s own live cells to accurately predict treatment response prior to beginning treatment.

  • Sam Patrick posted an article
    Greenville-based Zylö Therapeutics is utilizing regional chemical/mechanical engineering in new ways see more

    Once home to a thriving textile industry replete with chemical and mechanical engineers working to improve the soil and machinery converting raw cotton into commercial goods, upstate South Carolina may be on the precipice of its next industrial revolution: medtech.

     

    Born from technology developed at the Albert Einstein College of Medicine, Greenville-based Zylö Therapeutics is utilizing the regional chemical/mechanical engineering expertise and support network to improve drug and nitric oxide delivery through a proprietary sustained delivery system called Nanopods. 

    Read the entire story here, courtesy of Medical Design & Outsourcing...

  • Sam Patrick posted an article
    Leading-edge innovators, top presenters headed for SEMDA's Medtech 2018 in South Carolina see more

    Leading-edge innovators present for recognition, reward at annual gathering of Southeastern who’s who in medical technology, devices and diagnostics


    Greenville, SC – April 27, 2018 – At least 23 organizations ranging from start-ups to well-established companies have been accepted to present their latest, ground-breaking innovations to entrepreneurs, innovators, angel investors and business leaders from across the life sciences space as the Southeastern Medical Device Association (SEMDA) 2018 Medtech Conference convenes in Greenville, SC May 2-4, 2018.  

    SEMDA -- a non-profit trade association focused on making the Southeast a world-class region for medical technology, device, and diagnostic companies – has invited 23 finalist companies to present at PitchRounds 2018 – a highly targeted venue for both “Seed” companies as well as later-stage organizations to present innovative ideas to panels of institutional investors, regulatory leaders, venture capital directors, IP experts and others.

    Companies from seven Southeastern states will present ground-breaking ideas and technologies to hundreds of industry leaders.  Host state South Carolina leads the way with 10 companies invited to present, followed by Georgia and Florida with three companies each.  North Carolina, Alabama, Virginia and Tennessee are also represented.

    Among the South Carolina companies invited to present are Zylo Therapeutics, Accessible Diagnostics, KIYATEC and Moterum from host city Greenville, while Charleston’s Sanguine Technologies and Cryogenix, and Columbia’s Proof Biotechnologies are also invited.

    Invitees from Georgia include Intent Solutions and nfant, both of Atlanta, while North Carolina entries include Diamond Othopedic of CharlotteMemphis, Tennessee’s Sweetbio, Birmingham’s Circulogene and Nashville’s Raiven are also featured invitees.

    Twelve Early-stage companies from the Carolinas, Alabama and Florida have been invited to present at PitchRounds, with four finalists to be selected to compete for $10,000 in prize money, while getting to meet investors and partners at sessions and networking receptions.  SCBIO, SCRA and global law firm Eversheds Sutherland are co-sponsors of PitchRounds.

    Among the featured speakers committed to present at the conference are keynoter Joe Lee, Executive Director of Life Sciences for JP Morgan; Andy Fish, Chief Strategy Officer of AdvaMed; and Denise Hines, North American Chair of the Health Information & Management Systems Society and current CEO of eHealth Services Group.   

    Joe Lee is Executive Director of Life Sciences for JP Morgan and leads the Middle Market Banking coverage of life science companies across the Southeast. Widely respected in life science industry circles, Mr. Lee will discuss key opportunity areas for growth in the Southeast and provide rapid-growth companies with counsel on how to prepare their organizations for success in the competitive space.

    Andrew Fish is Chief Strategy Officer of AdvaMed, the leading trade association advancing medical technology in the U.S. and around the world. As chief strategy officer, Mr. Fish leads the association’s strategic planning, oversees AdvaMed's global, regulatory, and payment departments, and coordinates the development and operations of AdvaMed’s membership divisions and sectors.

    Dr. Denise Hines is current Chair of the North America Board of the Health Information & Management Systems Society (HIMSS), and is actively involved in HIMSS’ Women in Health IT initiatives that promote diversity and recognition.  She is CEO of eHealth Services Group and serves as Executive Director of Georgia’s statewide health information exchange (HIE).

    “The Southeastern medtech industry as a whole shows incredible growth and promise, and the diverse entries from across the region reflect that growth,” said Jason Rupp, Executive Director of SEMDA.  “PitchRounds gives us the chance to see the future come to life before our eyes with cutting-edge innovation and game-changing advancements in medical technology, devices and diagnostics from some of America’s brightest minds.”

    The SEMDA conference typically attracts more than 400 executives in medtech and life sciences from throughout the United States and has become a must-attend for the medtech community. Registration is strong but space is still available, noted Mr. Rupp.  Persons interested in attending can review the agenda, speakers and registration details online at http://www.semda.net.

    “These presenters and companies demonstrate that SEMDA has evolved into a truly regional organization that embraces and represents a diverse collective of medtech startups, universities, corporate organizations, investment resources, suppliers and capabilities from across the southeastern United States,” Mr. Rupp added.

    About SEMDA

    The Southeastern Medical Device Association (SEMDA) is a regional non-profit trade association that supports and promotes medical device and medical device data system (MDDS) companies in the Southeast. Created in 2004, the association provides unique educational resources to accelerate device development and achieve commercial success with access to funding, education, and networking opportunities for medical device companies, inventors, physicians, investors, tech transfer offices, universities, sponsors, and service providers interested in growing the medical device industry in the Southeast.

     

     

     

    Invited and scheduled to present at PitchRounds 2018

     

    LATER STAGE (RAISING SERIES A OR LATER)

    Company

    Name

    City/Town

    ST

    Kiyatec

    Matt Gevaert

    Greenville

    SC

    Intent Solutions

    Sam Zamarippa

    Atlanta

    GA

    Moterum

    David Huizenga

    Greenville

    SC

    Diamond Orthopedic

    JD Williams

    Charlotte

    NC

    Circulogene

    Mike Mullen

    Birmingham

    AL

    Sweetbio

    Kayla Rodriguez Graff

    Memphis

    TN

    Xhale, Inc.

    Douglas Crumb

    Gainesville

    FL

    Embody LLC

    Jeffrey Conroy

    Norfolk

    VA

    nfant

    Lou Malice

    Atlanta

    GA

    Kyndermed

    Melanie Simmons

    Tallahassee

    FL

    Raiven

    Jim Stefansic

    Nashville

    TN

    Fraudscope

    Musheer Ahmed

    Atlanta

    GA

     

     

     

     

     EARLY STAGE

    Company

    Name

    City/Town

    ST

    Zylö Therapeutics

    Scott Pancoast

    Greenville

    SC

    Sanguine Technologies Inc.

    John Forrest

    Charleston

    SC

    Accessible Diagnostics, LLC

    John Warner

    Greenville

    SC

    VitalFlo

    Luke Marshall, Ph.D.

    Raleigh

    NC

    Cryogenix, LLC

    John Baatz

    Charleston

    SC

    Aravis BioTech LLC

    Jeffrey Anker

    Greenville

    SC

    Purilogics, LLC

    Jinxiang Zhou

    Greenville

    SC

    OrthoScrews, LLC

    Zoe Guckien

    Tuscaloosa

    AL

    DiaTech Diabetes Technology

    John Gray

    Tallahassee

    FL

    Proof Biotechnologies, Inc

    Chang Kang

    Columbia

    SC

    PivotSC LLC/ XtremedX

    Frank Patterson

    Greenville

    SC

     

     

  • Sam Patrick posted an article
    SEMDA Medtech 2018 is coming to Greenville, SC May 2-4. see more

    Conference Registration Surging for Initial Appearance in Greenville, SC as Southeastern medtech industry continues rapid scale up


    Greenville, SC – April 17, 2018 -- The Southeastern Medical Device Association (SEMDA) -- a non-profit trade association focused on making the Southeast a world-class region for medical technology, device, and diagnostic companies – has announced an initial group of featured speakers for the 2018 SEMDA Medtech Conference May 2-4, 2018.

    For the first time ever, the annual Southeastern showcase of who’s who and what is happening in medtech will convene in South Carolina, with the Hyatt Regency Greenville serving as headquarters hotel.

    Among the featured speakers announced today that have committed to present at the conference are Joe Lee, Executive Director of Life Sciences for JP Morgan; Andy Fish, Chief Strategy Officer of AdvaMed; and Denise Hines, North American Chair of the Health Information & Management Systems Society and current CEO of eHealth Services Group.  Also speaking will be Lee Burnes, Vice President of Global Research & Development at Halyard Health; and Jim Stefansic, Chief Executive Officer of Raiven Healthcare

    Additional featured speakers are expected to be named shortly, and companies engaged in presenting to industry executives in the PitchRounds program, co-sponsored by SCRA, SCBIO and Eversheds Sutherland, will be announced within the week.  PitchRounds is a highly targeted event for both start-ups and “Seed” companies as well as later-stage (Series A or later) organizations to present ideas, innovations and products to panels of institutional investors, regulatory leaders, venture capital directors, IP experts and others in structured sessions.  Selected participants receive individual feedback on their presentations and compete for $10,000 in top prize money.

    “The South Carolina medtech industry has been a strong supporter of SEMDA for many years and is growing at one of the fastest rates in the country, so we are excited to tap into the growth and excitement in the industry by bringing this preeminent event to the Palmetto State for the first time,” said Jason Rupp, Executive Director of SEMDA.  “Most importantly, we are thrilled to unveil members of a stellar group of industry experts who will be presenting to members drawn from across the Southeastern United States and to industry attendees from across North America.”

    The SEMDA conference typically attracts more than 400 executives in medtech and life sciences from throughout the United States and has become a must-attend for the medtech community. Registration is currently surging, noted Mr. Rupp, and a full house of medtech industry leaders is again expected.  Persons interested in attending can review the agenda, speakers and registration details online at http://www.semda.net.

    Joe Lee, who will keynote Day 2 of the conference, is Executive Director of Life Sciences for JP Morgan and leads the Middle Market Banking coverage of life science companies across the Southeast. Well-known and respected in life science industry circles, Mr. Lee will discuss key opportunity areas for growth in the Southeast and provide rapid-growth companies with counsel on how to prepare their organizations for success in the competitive space.

    Andrew Fish is Chief Strategy Officer of AdvaMed, the leading trade association advancing medical technology in the U.S. and around the world. As chief strategy officer, Mr. Fish leads the association’s strategic planning, oversees AdvaMed's global, regulatory, and payment departments, and coordinates the development and operations of AdvaMed’s membership divisions and sectors.

    Dr. Denise Hines is current Chair of the North America Board of the Health Information & Management Systems Society (HIMSS), and is actively involved in HIMSS’ Women in Health IT initiatives that promote diversity and recognition.  She is CEO of eHealth Services Group and serves as Executive Director of Georgia’s statewide health information exchange (HIE).

    Lee Burnes is Vice President of Global R&D for Halyard Health where the organization is focused on development of products, technologies and solutions that prevent infection, eliminate pain and speed recovery.  Prior to joining Halyard, Lee successfully led numerous R&D organizations at Covidien.

    Jim Stefansic serves as President and CEO of Raiven Healthcare, a provider of healthcare artificial intelligence and data analytics solutions. An accomplished entrepreneur, Jim has years of experience launching and growing numerous healthcare technology businesses.  He previously was co-founder and COO of Pathfinder Therapeutics, Inc., where he helped bring industry-leading image-guided surgical products to market.

    “These presenters and others we will announce shortly demonstrates that SEMDA has evolved into a truly regional organization that embraces and represents the collective of medtech startups, universities, corporate organizations, investment resources and capabilities across the southeastern United States,” Mr. Rupp said.  “The conference provides a great opportunity to interact with other companies, investors, customers, partners, and specialized service providers.”

    # # #

     

    About SEMDA

    The Southeastern Medical Device Association (SEMDA) is a regional non-profit trade association that supports and promotes medical device and medical device data system (MDDS) companies in the Southeast. Created in 2004, the association provides unique educational resources to accelerate device development and achieve commercial success with access to funding, education, and networking opportunities for medical device companies, inventors, physicians, investors, tech transfer offices, universities, sponsors, and service providers interested in growing the medical device industry in the Southeast.

  • Sam Patrick posted an article
    South Carolina Innovators, Inventors convene at SEMDA conference to present to Venture Capitalists see more

    State’s Innovators, Inventors, convene at conference to present to Venture Capitalists

     

    GREENVILLE, SC – April 6, 2018 – The Southeastern Medical Device Association (SEMDA) -- a non-profit trade association driven to make the southeast a world-class region for medical technology, device, and diagnostic companies – brings its 2018 conference to South Carolina for the first time May 2-4, 2018, attracting hundreds of executives to Greenville to meet, negotiate, learn, network and grow the medical device industry in the Southeast.

    Focused on accelerating device development and helping organizations and individuals gain access to funding, education, and networking opportunities, the annual conference is a must-attend for medical device companies, inventors, physicians, investors, tech transfer offices, universities, and service providers interested in growing the medical device industry in North America, and even globally.

    As part of SEMDA 2018’s many activities, SCBIO and SCRA are collaborating to present PitchRounds 2018 – a highly targeted venue for both start-ups and “Seed” companies as well as later-stage (or Series A or later) organizations to present their ideas, innovations and products to panels of institutional investors, regulatory leaders, venture capital directors, IP experts and others in structured sessions. 

    Selected participants will receive individual feedback on their presentations and compete for $10,000 in top prize money for selected winners.  Participating presenters also receive two full conference registrations and access to meet with investors and partners at sessions and networking receptions.  Global law firm Eversheds Sutherland, one of the 50 largest law firms globally, is also a co-sponsor of PitchRounds.

    Applying to present is both free and simple, with full details available online at www.SEMDA.net/conference/pitchrounds or at www.SCBIO.org.  The deadline to complete the simple application to be considered is close of business April 13, 2018.

    SCBIO Vice President Erin Ford noted, “SCBIO and our co-sponsors are delighted to make PitchRounds a possibility for South Carolina’s emerging medtech companies to showcase their innovations and solutions, and to directly access investors and industry leaders to gain direct feedback on their innovations.”

    “While entries will be considered from across the entire Southeast and presentation spots are limited, we are confident that South Carolina will be well represented based on the robust pipeline of innovations the South Carolina life sciences community has been working on.  We encourage all early- and later-stage companies to enter the PitchRounds program and showcase the Palmetto State’s talents.”

    SCBIO is South Carolina’s investor-driven public/private economic development organization exclusively focused on building, advancing, and growing the life sciences industry in the state.  The industry has an $11.4 billion annual economic impact in the Palmetto State, with more than 400 firms and 15,000 professionals directly involved in the research, development and commercialization of innovative healthcare, medical device, industrial, environmental and agricultural biotech and products.  The state-wide nonprofit has offices in Greenville, Columbia, and Charleston, and represents companies in the advanced medicines, medical devices, equipment, diagnostics, IT, and healthcare outcome industries.

    SCBIO is the official state affiliate of BIO -- the world's largest trade association representing biotechnology organizations.  SCBIO members include academic institutions, biotech companies, med-tech companies, entrepreneurial organizations, service providers, thought leaders, economic development organizations and related groups whose members are leading the research and development of innovative healthcare, agricultural, industrial and environmental biotech and med-tech products that will make a difference across the Palmetto State, and around the world.

  • Sam Patrick posted an article
    Zylö Therapeutics is locating new operations in Greenville County, SC. see more

    GREENVILLE, S.C. – Zylö Therapeutics, a developer of state-of-the-art technology for the pharmaceutical industry, is locating new operations in Greenville County. The company is expected to create 30 new jobs.

     

    Zylö Therapeutics has developed an innovative sustained-release drug-delivery system that delivers traditionally hard-to-deliver therapeutic agents through topical administration. With more than 10 years of research and development, the second generation of this technology continues to improve, providing 24-hour sustained release of a variety of agents, including nitric oxide, curcumin, lidocaine and more.

     

    Zylö Therapeutics is headquartered at the NEXT on Main facility at 101 North Main Street in Greenville, S.C. NEXT is a program of the Greenville Chamber of Commerce that currently supports more than 100 knowledge-based companies in Upstate South Carolina.

    Zylö Therapeutics’ operations will soon include a lab facility, where formulation and product development work will be performed. Those interested in joining the Zylö Therapeutics team should visit www.zylotherapeutics.com for more information.

     

    QUOTES

     

    “With the bulk of our scientists and advisors located in the Northeast corridor, we considered a variety of alternative locations, but Greenville represents a wonderful balance of small-town feel, sophistication, high growth and vibrancy. In addition, the city offers a wealth of start-up resources that will assuredly work to our advantage over time.” – Zylö Therapeutics CEO Scott Pancoast

     

    “To see a company like Zylö Therapeutics choose to invest in our state and our people is an important sign to the business community around the world that South Carolina is the place to be. We’ve worked hard to create a pro-business environment and cultivate a highly-trained workforce, and those efforts continue to pay off.” –Gov. Henry McMaster

     

    “The success of South Carolina’s booming life sciences industry continues to impress, and I congratulate Zylö Therapeutics on today’s tremendous announcement. Over the last two decades, we’ve seen a major transformation in South Carolina’s economy, and innovative companies like Zylö Therapeutics are responsible for it.” –Secretary of Commerce Bobby Hitt

     

    “Greenville County encourages growth in the bioscience sector of our economy. We are proud to welcome Zylö Therapeutics to Greenville as part of our vibrant bioscience community that is pioneering state-of-the-art technologies at the forefront of modern medicine. We wish great success for Zylö Therapeutics.” –Greenville County Council Chairman H.G. “Butch” Kirven Jr.

     

    “Greenville has become increasingly attractive to industry leaders in next-generation medical care, as innovative companies like Zylö Therapeutics seek environments that can help connect resources, support emerging technologies and supply a dedicated workforce. The City of Greenville is thrilled to welcome Zylö to our vibrant downtown and we look forward to being a part of their company’s growth.” –City of Greenville Mayor Knox White

     

    “We are excited to welcome Zylö Therapeutics as the newest member of NEXT and the Greenville startup community. This high-impact, knowledge-based company further strengthens the more-than-150 companies within this vibrant, entrepreneurial ecosystem.” –NEXT CEO John Moore


    FIVE FAST FACTS

     

    • Zylö Therapeutics is locating new operations in Greenville County.
    • The start-up is projected to create 30 new jobs.
    • Zylö Therapeutics is a developer of patented, state-of-the-art technology for the pharmaceutical industry.
    • Headquartered in Suite 315 at 101 North Main Street in Greenville, S.C., the company’s operations will include a laboratory facility focused on formulation and product development.
    • Those interested in joining the Zylö Therapeutics team should visit www.zylotherapeutics.com for more information. 

  • Sam Patrick posted an article
    Hitachi Healthcare Americas Corp. has entered an agreement to acquire Greenville, SC's VidiStar, LLC see more

    Twinsburg, OH January 9, 2018 - Hitachi Healthcare Americas Corporation, a wholly owned subsidiary of Hitachi, Ltd. (TSE: 6501) and a leading provider of medical imaging modalities to hospital and ambulatory clients nationwide, today announced that it has entered into an agreement to acquire VidiStar, LLC, a Greenville, SC-based company focused on reinventing how doctors review and report on diagnostic exams to drive productivity, portability, and improved communication and clinical decision making. Hitachi expects that the acquisition of VidiStar will advance the company's informatics strategy and analytics capabilities to improve workflow and intelligence for physicians, particularly with those providers conducting diagnostic ultrasound examinations.

    "VidiStar has developed a cloud-based diagnostic viewer and customizable structured reporting solution for medical imaging and clinical decision support. With VidiStar, physicians can interpret exams over the web and deliver improved visualization and timely results with the extended care teams.” said William Burns, Senior VP, Hitachi Healthcare Americas.

    “We are very excited about VidiStar becoming part of the Hitachi team and believe this partnership will further our client’s ability to reduce inefficiencies in clinical and operational workflows. We will work together to create the next generation of healthcare informatics and analytics solutions so providers and healthcare professionals can take full advantage of the power of informatics." said Craig Walker, CEO of Vidistar.

    “This acquisition will add significant talent and expertise in expanding our Healthcare Informatics business at Hitachi. As the healthcare market transitions from volume to value-based care, structured reporting and advanced analytics will play a critical role in enabling and supporting this transition.” said Yasuhiko Taniguchi, CEO of Hitachi Healthcare Americas.

    Structured reporting can help standardize and improve the quality of clinical reports and streamline communication among care teams while reducing errors. Advanced analytics and data mining can help identify key value drivers, improve decision making, and ensure that providers and healthcare professionals are informed and efficient in their mission to deliver high quality care.

    Upon completion of the transaction, VidiStar and its employees will become part of the Hitachi Healthcare Americas business group within Hitachi. VidiStar will maintain its current headquarters office in Greenville, SC.

    About VidiStar, LLC 

    VidiStar, LLC is based in Greenville, SC (USA) and has developed a web-based diagnostic viewer and patented structured reporting solution (US Pat. No. 8,200,505) for medical imaging and clinical decision support. VidiStar's technology allows physicians and healthcare providers the ability to read and interpret diagnostic studies over the internet for timely interpretation, improved patient diagnosis, clinical decision support, and advanced patient data analytics and notification. VidiStar is a 2012 and 2013 Innovision Award Winner and a 2008 and 2010 SCLaunch Portfolio Company.

    About Hitachi Healthcare Americas Corporation

    Hitachi Healthcare Americas Corporation, located in Twinsburg, Ohio, a wholly owned subsidiary of Hitachi, Ltd. offers a broad range of diagnostic imaging equipment including MRI, CT and Ultrasound. Hitachi’s MRI, CT and Ultrasound technologies provide speed, comfort and quality for both physicians and patients alike and play an important role in the diagnosis and treatment of disease while driving social innovation into healthcare. Visit www.hitachihealthcare.com.

     About HitachiLtd

    Hitachi, Ltd. (TSE: 6501), headquartered in Tokyo, Japan, delivers innovations that answer society’s challenges. The company’s consolidated revenues for fiscal 2016 (ended March 31, 2017) totaled 9,162.2 billion yen ($81.8 billion). The Hitachi Group is a global leader in the Social Innovation Business, and it has approximately 304,000 employees worldwide. Through collaborative creation, Hitachi is providing solutions to customers in a broad range of sectors, including Power / Energy, Industry / Distribution / Water, Urban Development, and Finance / Government & Public / Healthcare. For more information on Hitachi, please visit the company’s website at http://www.hitachi.com/.